Adverum Biotechnologies, Inc.
Clinical trials sponsored by Adverum Biotechnologies, Inc., explained in plain language.
A clinical-stage gene therapy company focused on ocular diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Gene therapy shot could end monthly eye injections for wet AMD Results expected Dec 2026 (estimated) 🚀 Make-or-break
-
Gene therapy shot could end monthly eye injections for wet AMD
Disease control OngoingThis Phase 3 trial tests a single injection of Ixo-vec gene therapy in 311 people with wet age-related macular degeneration (AMD). The goal is to see if it can maintain or improve vision as well as standard aflibercept injections, but with fewer follow-up treatments. Participants…
Phase 3 • Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Gene therapy for wet AMD: could this mean fewer eye injections?
Disease control OngoingThis study follows 23 people with wet age-related macular degeneration who received a single dose of ADVM-022 gene therapy in an earlier trial. Researchers are checking how safe the treatment is over time and whether it continues to control the disease, potentially reducing the n…
Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC